| |
U.S. Patent
United States Patent #: 5,340,579
Date of Patent: Aug. 23, 1994
Casero, deceased
Method of treating dermatological conditions
Inventors: Casero, deceased; Riccardo (late of Como, IT), by
Patrizia Magnasco Casero, executor, Francesca Margaret Casero,
Elisabetta Giovanna, heirs.
Assignee: Farmaka S.r.l. (Grandate, IT)
Appl. No.: 541,119
Filed: Jun. 20, 1990
Related U.S. Application Data
Continuation-in-part of Ser No. 83,944, Aug. 4, 1987, abandoned,
which is a continuation of Ser. No. 797,685, Nov. 13, 1985,
abandoned.
Foreign Application Priority Data
Nov. 20, 1984 [IT] 23676 A/84
Intl. Cl.: A61K 35/00; A61K 37/00; A61K 37/02; A61K 37/10
U.S. Cl.: 424/114; 514/ 2; 514/ 8; 514/ 21; 514/336; 514/844;
514/847; 514/858; 514/859; 514/860; 514/861; 514/862; 514/863;
514/864; 514/865
Field of Search: 514/2, 8, 21, 336, 847, 844, 858-865; 424/114,
115-117, 70
References Cited [Referenced By:]
U.S. Patent Documents
3,887,703 Jun., 1975 Manoussos et al. 424/180
4,303,676 Dec., 1981 Balazs 424/359
4,504,494 Mar., 1985 Grollier et al. 514/544
Foreign Patent Documents
158706 Dec., 1981 JP
1198005 Mar., 1968 GB
1283892 Aug., 1972 GB
200232A Feb., 1979 GB
Other References
The Merck Index, 19th Ed., Merck and Co., Rahway, N.J. 1976, p. 624,
entry No. 4634.
Clinical Pharmacology Research, "Assessment of the Effects of a
Topical Product Containing Glycosaminoglycans in Cutaneous
Hydration", Berardesca, E. et al.
Primary Examiner: Moezie; F. T. Attorney, Agent or Firm: Browdy and
Neimark
Abstract
A method is provided for treating dermatological conditions by
binding and blocking 5-a-dihydrotestosterone receptors comprising
applying to the skin an effective amount of composition comprising:
(a) from about 0.1% to about 2.0% by weight of mucopolysaccharides
free of proteins and having a pH ranging from about 5 to 7.5 in
aqueous solution, a rotary power between about to +15, and a sulfur
content greater than 6%;
(b) from about 1% to about 3% by weight of an aqueous extract of
human umbilical cord free from sulfur and having a DH of from about
5 to about 7, a viscosity of 30 deg. C. of from 10 to 25
centistokes, a hyaluronic acid titre of from about 500 to about 700
mg/dl, and an ash content of less than about 0.5%;
(c) from about 0.05 to about 0.08% by weight of tetrahydrofurfuryl
nicotinate; and
(d) pharmaceutically and cosmetically acceptable vehicles and
excipients.
This method is particularly useful in treating dermatological
conditions such as acne, wrinkles, lipodiystrophies, dermosclorosis,
androgenic alopecia, hypertrichosis, and the like.
More Kevis information can be found on the pages
below:
About Hair Loss
Kevis Hair
Rejuvenation Program
Articles on Kevis Hair
Rejuvenation
Testimonials from
Clients
U.S. Patent
Clinical Research for
Physicians
The NaturoDoc Hair Comeback Program
|
